Sophoridine suppresses lenvatinib‐resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression

Hepatocellular carcinoma (HCC) is one of the most lethal cancer types with insufficient approved therapies, among which lenvatinib is a newly approved multi‐targeted tyrosine kinase inhibitor for frontline advanced HCC treatment. However, resistance to lenvatinib has been reported in HCC treatment r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Zhongwei, Zhang, Dengke, Wu, Fazong, Tu, Jianfei, Song, Jingjing, Xu, Min, Ji, Jiansong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810959/
https://www.ncbi.nlm.nih.gov/pubmed/33210432
http://dx.doi.org/10.1111/jcmm.16108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810959/
https://www.ncbi.nlm.nih.gov/pubmed/33210432
http://dx.doi.org/10.1111/jcmm.16108

Ejemplares similares